Abogen Biosciences Appoints Dr. Julie Yan Pan as Senior Vice President of Business Development
Abogen
Nucleic Acid Drug Developer
2024Year9Month2Day, Abogen Biosciences Co., Ltd. (hereinafter referred to as "Abogen")Announcement, AppointmentJulie Yan PanPh.D. serves as Senior Vice President of Business Development,Lead the business development team,Fully responsible for implementing the company's strategic plans, out-licensing cooperation of the product pipeline, and strategic innovation alliances, to promote the rapid implementation of the company's strategy and accelerate the R&D and commercialization process of the company’s products.
Julie Yan PanDr. has more than25Year'sCross-functional Leadership Experience, covering large multinational pharmaceutical companies and ChinaDomestic Innovative Pharmaceutical Enterprises. She is in the planning of new products./Rich experience in strategic marketing, pipeline portfolio planning, and product lifecycle management, participating in the R&D and commercialization of multiple oncology and central nervous system products, and facilitating various commercial collaboration projects, including Haihe this year.DrugAndJapanDaiichi SankyoAchieved Glumetinib in Asia andParts of Oceania's authorized business. Before joining Abogen Biosciences,PanDr.Haihe PharmaceuticalSenior Vice President of Business Development and Head of U.S. Operations;JoinHaihe PharmaceuticalPreviously,PanDr. [Name] has held key positions at Antengene, Henry Pharmaceuticals, Teva Pharmaceutical Industries, GlaxoSmithKline, Merck, and AstraZeneca, demonstrating strong scientific expertise and sharp business acumen.
PanPh.D.Holding a Ph.D. in Nutritional Biochemistry from Harvard University, a Bachelor's degree in Microbiology from Fudan University, and a Master's degree in Business Administration from the Wharton School (MBA）。
“I am very pleased to join Abogen Biosciences, a global leader in mRNA drug development, at this historic moment when mRNA technology is just entering commercialization. During the pandemic, Abogen's self-developed COVID-19 vaccine, which received EUA overseas, validated the company’s safe and effective mRNA technology platform as well as its large-scale production capabilities. I believe that Abogen's unique technology platform and its product pipelines in infectious diseases and tumor immunology hold tremendous market potential and are expected to gain favor from many international pharmaceutical companies. I will make full use of my decades of experience in new drug development, oncology, and business development to collaborate closely with the company’s scientists, seeking opportunities for external partnerships and technology transfers, and contributing positively to the company’s business development and long-term growth.”
“We are very pleased to invite Dr. Julie Yan Pan to join Abogen.Dr. Pan has a global perspective and decades of experience in the biopharmaceutical field, with rich expertise in product planning, strategic marketing, and business development, achieving multiple business collaborations, including this year's partnership between Haihe Pharma and Japan's Taiho Pharmaceutical, showcasing exceptional business development talent.Recently, the company has had a series of exciting developments, including the publication of its self-developed innovative circular RNA synthesis technology in a top international journal, the release of Phase III clinical trial results for its mRNA vaccine targeting COVID-19 variants, which also validated the Abogen technology platform, and the establishment of a strategic partnership with Ruijin Hospital to accelerate the transformation of scientific research achievements.As Abogen's platform technology continues to be solidified and validated, we are confident about the future and believe that Dr. Pan's years of accumulated experience and resources will accelerate the progress of Abogen's product pipeline in external collaborations.We are looking forward to working with Dr. Pan to witness more self-developed technologies and products by Abogen Biosciences reaching the global stage, contributing to overcoming diseases and safeguarding health.”
About Us
Abogen Biosciences (referred to as "Abogen") is an innovative biopharmaceutical company specializing in the research and development of messenger ribonucleic acid (mRNA) drugs. The company owns industry-leading, proprietary intellectual property rights over its mRNA and nanodelivery technology platforms. It is one of the few mRNA drug R&D enterprises in China with comprehensive value chain capabilities, covering all aspects from mRNA design, formulation development, to large-scale production. The company has established a rich product pipeline, encompassing infectious disease prevention and treatment, tumor immunotherapy, including mRNA COVID-19 vaccines.Protein replacement therapy and other fields.
